Plants that Fight Cancer, Second Edition

ISBN-13: 9781032091549 / Angielski / Miękka / 2021 / 530 str.

Spyridon E. Kintzios; Maria G. Barberaki

Opis

Plants that Fight Cancer is an up-to-date, extensive review of plant genera and species with documented anti-tumor and anti-leukaemic properties.

Spis treści

1. Cancer: A Brief Overview of the Disease and its Treatment1.1. Incidence and causes: cancer in a nutshell1.2. Classification of cancer types1.2.1. Cancers with less than 20% five-year survival rate1.2.2. Cancers with five-year survival rates (at all stages) between 20 and 50%1.2.3. Cancers with five-year survival rates between 50 and 80%1.2.4. Cancers with five-year survival rates higher than 80%1.3. Therapy1.3.1. Conventional cancer treatments1.3.2. Advanced cancer treatments1.3.2.1. Protein kinase inhibitors and other enzymes1.3.2.2. Immunotherapy1.3.2.3. Angiogenesis inhibitors1.3.2.4. Hormones1.3.3. Other advanced therapies1.3.4. Alternative cancer treatments1.4. From source to patient: testing the efficiency of a candidate anticancer drug1.4.1. Preclinical tests1.4.2. Phases of Clinical Trials1.4.3. Clinical Trial Protocols2. The Plant Kingdom: Nature’s Pharmacy for Cancer Treatment2. 1. Brief overview of the general organization of the plant cell2.2. The chemical constituents of the plant cell2.2.1. Primary metabolites2.2.2. Secondary metabolites2.3. Why do plant compounds have an anticancer activity?2.4. Chemical groups of natural products with anticancer2.5. Biotechnology and the supply issue3. Cytotoxic Phenanthridone Alkaloid Constituents of the Amaryllidaceae3.1. Introduction3.2. Isolation of phenanthridones3.3. Structural features of phenanthridones3.4. Synthesis of phenanthridone alkaloids3.5. Cytotoxic effects of phenanthridone alkaloids in vitro3.5.1. Narciclasine and its congeners3.5.2. Pancratistatin and its congeners3.5.3. Narciprimine and its congeners3.6. Structure-activity relationship studies3.6.1. Truncated analogs3.6.2. Ring-A modifications3.6.3. Ring-B modifications3.6.4. Ring-C modifications3.7. Cytotoxic effects of phenanthridone alkaloids in vivo3.7.1. In vivo effects of narciclasine3.7.2. In vivo effects of pancratistatin3.8. Mechanism of action of phenanthridone alkaloids3.8.1. Permeability and solubility3.8.2. Efflux pump interactions3.8.3. Mitotic effects3.8.4. Effects on protein synthesis3.8.5. Topoisomerase inhibition3.8.6. Effects on calprotectin3.8.7. Effects on nitric oxide3.8.8. Effects on tumor necrosis factor (TNF)3.8.9. Apoptosis inducing effects3.8.9.1. Apoptosis inducing effects of narciclasine3.8.9.2. Apoptosis inducing effects of pancratistatin3.8.9.3. Apoptosis inducing effects of ring-C unsaturated analogs3.8.10. Tumor invasion and metastasis3.9. Conclusions3.10. Acknowledgements3.11. Conflict of interest3.12. Abbreviations4. Naphthoquinone-Contained Anticancer Terrestrial Plants5. Polyphenols and cancer immunology5.1. Introduction5.1.1. Tumor microenvironment5.2. Tumor-infiltrating cells5.2.1. Macrophages5.2.2. Dendritic cells (DCs)5.2.3. NK cells5.2.4. Myeloid Derived Suppressor Cells (MDSCs)5.2.5. T and B lymphocytes5.2.5.1. T lymphocytes5.2.5.1.1. CD8+ Cytotoxic T-Lymphocytes (CTLs)5.2.5.1.2. CD4+ helper T-lymphocytes5.2.5.1.3. CD4+ CD25+ FoxP3+ T lymphocytes (Tregs)5.2.5.1.4. T-lymphocytes5.2.5.2. B-lymphocytes5.2.6. Cancer Associated Fibroblasts (CAFs)5.3. Natural compounds in cancer therapy5.3.1. Polyphenols5.3.1.1. Resveratrol5.3.1.2. Curcumin5.3.1.3. Quercetin5.3.1.4. Green tea polyphenols (GTPs) – (-)-Epigallocatechin 3- gallate (EGCG)5.3.1.5. Apigenin5.3.1.6. Silibinin5.3.1.7. Other polyphenols5.4. Conclusions6. Medicinal plant-product based fabrication nanoparticles (Au and Ag) and their anticancer effects6.1. Introduction6.2. Medicinal plants and Au/or Ag-NPs synthesis6.3. Mechanisms of action6.4. Conclusion7. Bladder and Prostate Cancer7.1. Introduction7.2. Method7.3. Results7.3.1. Selenium and Vitamin E7.3.2. Pomegranate7.3.3. Green Tea7.3.4. Curcumin7.3.5. Resveratrol7.3.6. Silibinin7.3.7. Ginkgo Bilboa7.3.8.Modified Citrus Pectin7. 3.9. Phellodendron amurense7.3.10. Red Clover7.3.11. Salvia7.3.12. Mistletoe7.3.13. Combined Therapies7.4. Conclusion8. Plant Lectins in Cancer ¿reatment, the case of Viscum album L.8.1. Introduction to lectin research8.2. Lectin abundance and classification8.3. Plant Lectins in cancer diagnosis and treatment8.3.1 Plant lectins in cancer diagnosis8.3.2 Plant lectins in cancer treatment8.4. Viscum album lectins in cancer treatment8.5. Conclusion9. Plants Species with Anticancer Activity9.1. Introduction: General Botanical Issues9.1.1. Life cycle9.1.2. Plant anatomy9.2. Species-specific information9.2.1. Success Stories: Plant species used in contemporary clinical cancer treatment9.2.2. Species with Anticancer Active IngredientsAppendix: Chemical structures of selected compounds

O autorze

Professor Spyridon Kintzios is the Rector of the Agricultural University of Athens (AUA) and the founder and Director of the Laboratory of Cell Technology and the AUA Center for Applications of Cell Biological Technologies. He received his Ph.D. in Genetics and Plant Breeding from the Technical University of Munich. He has a working experience of over 30 years in Biotechnology. He is the author/co-author of 110 peer-reviewed articles in cited international scientific journals, as well as the author or co-author of more than 100 international book chapters and conference presentations. He is also the editor of five international books, a fellow of several Scientific Societies and a member of several public, academic and industry committees in Greece and abroad.

Dr Maria Barberaki graduated from the Department of Agricultural Biotechnology, Agricultural University of Athens, Greece. Her PhD study was focused on the production of secondary products with medicinal use from Viscum album using biotechnological methods. Dr Barberaki has a several year-long working experience at international pharmaceutical companies. She was one of the Editors of the first Edition of Plants that Fight Cancer. She is currently working in Secondary and Vocational Education.

Dr Evangelia Flampouri holds a PhD in Agricultural Sciences specializing in Mammalian Toxicology, a Master of. Arts degree in Bioactive products and Protein Technology and a Bachelor of Arts degree in Agricultural Biotechnology. She has over 10 years of experience in Academic and Industrial research projects. She has worked as a contracted Associate Professor at the Agricultural University of Athens, teaching Pharmacognosy and Bioactive Products. She is the author/co-author of various peer-reviewed articles in cited international scientific journals.